Guideline-directed antihypertensive medication use among young adult participants with uncontrolled hypertension at enrollment in the MyHEART study.

IF 2 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Megan R Knutson Sinaise, Jennifer Zaborek, KyungMann Kim, Diane R Lauver, Patrick McBride, Jane Pearson, Allexa Licon, Anupama Joseph, Heather M Johnson, Kara K Hoppe
{"title":"Guideline-directed antihypertensive medication use among young adult participants with uncontrolled hypertension at enrollment in the MyHEART study.","authors":"Megan R Knutson Sinaise, Jennifer Zaborek, KyungMann Kim, Diane R Lauver, Patrick McBride, Jane Pearson, Allexa Licon, Anupama Joseph, Heather M Johnson, Kara K Hoppe","doi":"10.1186/s12872-024-04313-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertension is a major risk factor for heart disease, heart failure and stroke. Lifestyle changes are recommended as first-line treatment for management of high blood pressure for young adults, when 10-year atherosclerotic cardiovascular disease risk score is < 10%. If lifestyle changes alone do not control blood pressure, then providers have access to four classes of first-line blood pressure lowering agents to treat hypertension, when other contra-indications are not present.</p><p><strong>Methods: </strong>This is a cross-sectional, retrospective, secondary analysis performed of the MyHEART trial on study participants at enrollment to determine they were prescribed anti-hypertensive medication. Of those prescribed medications, we aimed to determine the frequency first-line medications including thiazide or thiazide-like diuretics, angiotensin converting-enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers were prescribed. This analysis categorized participants into four medication status categories: no antihypertensive medication, prescribed only first-line antihypertensives, prescribed only non-first-line antihypertensives, and prescribed a combination of first-line and non-first-line antihypertensives. Participant clinical and sociodemographic factors by medication use were evaluated. Linear regression models were fit to determine the association between antihypertensive medication and blood pressure.</p><p><strong>Results: </strong>At enrollment, 157/311 (50.5%) participants were not on antihypertensives. Of the 154 on antihypertensives, reported use included monotherapy 97/154 (63.0%), combined therapy 57/154 (37.0%), only first-line antihypertensive 111/154 (72.0%), and only non-first-line antihypertensives 21/154 (13.6%), and combination of first-line and non-first-line antihypertensives 22/154 (14.2%). Antihypertension medication use varied based on age (p < 0.001), sex (p = 0.008), race (p = 0.001), body mass index (BMI) kg/m<sup>2</sup> (p = 0.016), anxiety and/or depression (p = 0.048), diabetes (p = 0.007), and sodium intake (p = 0.042). Participants with only first-line medications had lower in-office systolic (-4.66 mmHg, CI -8.31 to -1.02, p = 0.013) and diastolic (-3.51 mmHg, CI -6.30 to -0.71, p = 0.015), and lower ambulatory diastolic (-2.12 mmHg, CI -4.15 to -0.09, p = 0.041) blood pressure than those without antihypertensives.</p><p><strong>Conclusions: </strong>Among MyHEART study participants, all of which had uncontrolled hypertension, 50.5% were not on an antihypertensive at enrollment. This finding supports the call to improve management of blood pressure earlier in life to potentially contribute to the reduction of long-term cardiovascular disease. Of the participants who were prescribed blood pressure medication, providers prescribed guideline-based antihypertensive therapy the majority of the time, however, this study indicates there may be an opportunity to increase the use of first-line, guideline-based antihypertensives, regardless of age, sex, or type of hypertension to lower long-term cardiovascular risk.</p><p><strong>Trial registration: </strong>https://www.</p><p><strong>Clinicaltrials: </strong>gov Identifier: NCT03158051, registered 5-15-2017. IRB approval obtained: IRB # 2017 - 0372.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11559136/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cardiovascular Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12872-024-04313-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hypertension is a major risk factor for heart disease, heart failure and stroke. Lifestyle changes are recommended as first-line treatment for management of high blood pressure for young adults, when 10-year atherosclerotic cardiovascular disease risk score is < 10%. If lifestyle changes alone do not control blood pressure, then providers have access to four classes of first-line blood pressure lowering agents to treat hypertension, when other contra-indications are not present.

Methods: This is a cross-sectional, retrospective, secondary analysis performed of the MyHEART trial on study participants at enrollment to determine they were prescribed anti-hypertensive medication. Of those prescribed medications, we aimed to determine the frequency first-line medications including thiazide or thiazide-like diuretics, angiotensin converting-enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers were prescribed. This analysis categorized participants into four medication status categories: no antihypertensive medication, prescribed only first-line antihypertensives, prescribed only non-first-line antihypertensives, and prescribed a combination of first-line and non-first-line antihypertensives. Participant clinical and sociodemographic factors by medication use were evaluated. Linear regression models were fit to determine the association between antihypertensive medication and blood pressure.

Results: At enrollment, 157/311 (50.5%) participants were not on antihypertensives. Of the 154 on antihypertensives, reported use included monotherapy 97/154 (63.0%), combined therapy 57/154 (37.0%), only first-line antihypertensive 111/154 (72.0%), and only non-first-line antihypertensives 21/154 (13.6%), and combination of first-line and non-first-line antihypertensives 22/154 (14.2%). Antihypertension medication use varied based on age (p < 0.001), sex (p = 0.008), race (p = 0.001), body mass index (BMI) kg/m2 (p = 0.016), anxiety and/or depression (p = 0.048), diabetes (p = 0.007), and sodium intake (p = 0.042). Participants with only first-line medications had lower in-office systolic (-4.66 mmHg, CI -8.31 to -1.02, p = 0.013) and diastolic (-3.51 mmHg, CI -6.30 to -0.71, p = 0.015), and lower ambulatory diastolic (-2.12 mmHg, CI -4.15 to -0.09, p = 0.041) blood pressure than those without antihypertensives.

Conclusions: Among MyHEART study participants, all of which had uncontrolled hypertension, 50.5% were not on an antihypertensive at enrollment. This finding supports the call to improve management of blood pressure earlier in life to potentially contribute to the reduction of long-term cardiovascular disease. Of the participants who were prescribed blood pressure medication, providers prescribed guideline-based antihypertensive therapy the majority of the time, however, this study indicates there may be an opportunity to increase the use of first-line, guideline-based antihypertensives, regardless of age, sex, or type of hypertension to lower long-term cardiovascular risk.

Trial registration: https://www.

Clinicaltrials: gov Identifier: NCT03158051, registered 5-15-2017. IRB approval obtained: IRB # 2017 - 0372.

MyHEART 研究中高血压未得到控制的年轻成年参与者在指南指导下使用降压药的情况。
背景:高血压是心脏病、心力衰竭和中风的主要风险因素:高血压是心脏病、心力衰竭和中风的主要风险因素。当 10 年动脉粥样硬化性心血管疾病风险评分为方法时,建议将改变生活方式作为年轻人控制高血压的一线治疗方法:这是对 MyHEART 试验进行的一项横断面、回顾性、二次分析,目的是确定研究参与者在注册时是否服用了抗高血压药物。在处方药物中,我们旨在确定一线药物(包括噻嗪类或噻嗪类利尿剂、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂和钙通道阻滞剂)的处方频率。这项分析将参与者的用药情况分为四类:未服用降压药、仅服用一线降压药、仅服用非一线降压药、服用一线和非一线降压药的组合。根据用药情况对参与者的临床和社会人口因素进行了评估。拟合线性回归模型以确定降压药与血压之间的关系:在注册时,157/311(50.5%)名参与者未服用降压药。在使用降压药的 154 人中,报告的使用情况包括单药治疗 97/154 人(63.0%)、联合治疗 57/154 人(37.0%)、仅使用一线降压药 111/154 人(72.0%)、仅使用非一线降压药 21/154 人(13.6%)以及联合使用一线和非一线降压药 22/154 人(14.2%)。抗高血压药物的使用因年龄(p 2 (p = 0.016))、焦虑和/或抑郁(p = 0.048)、糖尿病(p = 0.007)和钠摄入量(p = 0.042)而异。与未服用降压药的参与者相比,仅服用一线药物的参与者的诊室收缩压(-4.66 mmHg,CI -8.31至-1.02,p = 0.013)和舒张压(-3.51 mmHg,CI -6.30至-0.71,p = 0.015)以及非卧床舒张压(-2.12 mmHg,CI -4.15至-0.09,p = 0.041)均较低:MyHEART研究的所有参与者都患有未控制的高血压,其中50.5%的人在入组时没有服用降压药。这一发现支持了改善生命早期血压管理的呼吁,可能有助于减少长期心血管疾病。在开了降压药的参与者中,医疗服务提供者在大多数情况下都开了基于指南的降压药,但这项研究表明,可能有机会增加一线、基于指南的降压药的使用,无论年龄、性别或高血压类型如何,以降低长期心血管风险。试验注册:https://www.Clinicaltrials: gov Identifier:NCT03158051,注册日期:2017 年 5 月 15 日。已获得 IRB 批准:IRB # 2017 - 0372。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.50
自引率
0.00%
发文量
480
审稿时长
1 months
期刊介绍: BMC Cardiovascular Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the heart and circulatory system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信